Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Cystectomy
100%
Bladder Cancer
65%
Neoplasm
58%
Transitional Cell Carcinoma
54%
Muscle Invasive Bladder Cancer
40%
Malignant Neoplasm
37%
Diseases
36%
Non Muscle Invasive Bladder Cancer
33%
Bladder
33%
Recurrent Disease
33%
Clear Cell Renal Cell Carcinoma
31%
Overall Survival
28%
Circulating Tumor DNA
28%
Partial Nephrectomy
26%
Urinary Diversion
25%
Tumor
24%
Prostate Cancer
23%
Hazard Ratio
22%
Pelvis
22%
Retroperitoneal Lymph Node Dissection
22%
Biological Marker
18%
Nephroureterectomy
18%
Recurrence Free Survival
18%
Neoadjuvant Chemotherapy
18%
Urothelial Cancer
18%
Kidney Tumour
16%
Gemcitabine
16%
Neobladder
16%
Clinical Trial
14%
Lymph Node
14%
Minimal Residual Disease
14%
Cisplatin
14%
Urology
14%
Testis Cancer
13%
Biopsy Technique
12%
Metastatic Carcinoma
12%
Cancer Specific Survival
12%
Kidney Function
11%
Radical Nephrectomy
11%
Immunotherapy
10%
Proportional Hazards Model
10%
Docetaxel
9%
Bladder Tumor
9%
Chloroplast DNA
9%
Glomerular Filtration Rate
9%
Cancer
9%
Mycobacterium Bovis BCG
8%
Germinoma
8%
Tumor Microenvironment
8%
Surgeon
8%
Keyphrases
Bladder Cancer
66%
Upper Tract Urothelial Carcinoma
52%
Radical Cystectomy
48%
Robot-assisted Radical Cystectomy
39%
Non-muscle Invasive Bladder Cancer (NMIBC)
38%
Muscle-invasive Bladder Cancer
32%
Tumor
29%
Circulating Tumor DNA (ctDNA)
27%
Overall Survival
26%
Cystectomy
25%
Oncological Outcomes
24%
Confidence Interval
23%
Renal Cell Carcinoma
22%
Recurrence-free Survival
22%
Hazard Ratio
22%
Nephroureterectomy
17%
Neoadjuvant Chemotherapy
17%
Tumor-informed
16%
Bacillus Calmette
16%
Gemcitabine
15%
National Cancer Database
14%
Intracorporeal Urinary Diversion
14%
Postoperative Outcomes
14%
Robot-assisted
13%
Bladder
13%
Prostate Cancer
13%
Docetaxel
13%
Cancer-specific Survival
13%
Functional Outcome
13%
Clinical Trials
13%
Urinary Diversion
12%
Complication Rate
12%
Urothelial Cancer
11%
Renal Mass
11%
Clear Cell Renal Cell Carcinoma (ccRCC)
11%
Tumor Microenvironment
11%
Multivariable
10%
High Risk
10%
Robotic-assisted
10%
Pelvic Lymph Node Dissection
10%
Bladder Tumor
10%
Partial Nephrectomy
10%
Testicular Cancer
9%
Urothelial Carcinoma
9%
Robotics
9%
Tumor Characteristics
9%
Cancer Patients
9%
Robot-assisted Partial Nephrectomy
9%
Natural Killer Cells
9%
Intermediate Risk
8%